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There is increasing evidence supporting dietary and alternative therapies for epilepsy, 
including the ketogenic diet, modified Atkins diet, and omega-3 fatty acids. Vitamin 
D3 is actively under investigation as a potential intervention for epilepsy. Vitamin D3 is 
fat-soluble steroid, which shows promise in animal models of epilepsy. Basic research 
has shed light on the possible mechanisms by which Vitamin D3 may reduce seizures, 
and animal data support the efficacy of Vitamin D3 in rat and mouse models of epilepsy. 
Very little clinical data exist to support the treatment of human epilepsy with Vitamin D3, 
but positive findings from preliminary clinical trials warrant larger Phase I and II clinical 
trials in order to more rigorously determine the potential therapeutic value of Vitamin D3 
as a treatment for human epilepsy.
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iNTRODUCTiON
Epilepsy affects approximately two million Americans and 65 million people worldwide (1). Among 
those with epilepsy, 22–30% have drug-resistant epilepsy (DRE) (1, 2). DRE causes cognitive and 
mood impairment, injuries, and increased risk of death including sudden death in epilepsy (SUDEP) 
(1–3). Antiepileptic drugs (AEDs) are the primary medical treatment for epilepsy. However, even 
for those whose seizures are well controlled by AEDs, allergies, neurological and systemic toxicity, 
depression, memory loss, and osteoporosis are common problems (4, 5). Because of the limitations 
and potential toxicity of existing AEDs, there is significant clinical interest in finding alternative 
therapies for epilepsy.
In the search for alternative epilepsy treatments, Vitamin D3 is an intriguing candidate (6). As 
early as 1974, Christiansen postulated that supplementation of Vitamin D might improve calcium 
and magnesium levels and may decrease hyperexcitability in patients with epilepsy. In the four 
decades since, progress has been made in understanding the biochemical and cellular mechanisms 
of Vitamin D3’s anticonvulsant properties. Animal data have supported the anticonvulsant effects of 
Vitamin D3 in mice and rats (7–11). Existing evidence for the use of Vitamin D3 in treating human 
epilepsy is very limited (6, 12). There is a critical need for larger clinical trials to establish the safety 
and efficacy of vitamin D3 in epilepsy. In this review, we will critically analyze the animal and human 
evidence to date supporting the use of Vitamin D3 as a treatment for epilepsy.
FiGURe 1 | vitamin D metabolism.
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viTAMiN D3 OveRview: BiOCHeMiSTRY 
AND ROLe iN HUMAN HeALTH
The most biologically active form of Vitamin D in humans is 
Vitamin D3 (cholecalciferol), which is a fat-soluble steroid hor-
mone (13). Dietary sources of Vitamin D3 include dairy, meat, 
fish, and mushrooms (14). The primary source of Vitamin D3 is 
exposure of the skin to ultraviolet sunlight (14). The metabolic 
pathway of Vitamin D3 is summarized in Figure 1. 7-dehydro-
cholesterol is converted to Vitamin D3 in the skin after exposure to 
sunlight. Vitamin D3 is converted to 25-hydroxy-cholecalciferol 
(25-OH Vitamin D3) in the liver. 25-OH Vitamin D3 is the major 
circulating form of Vitamin D, but it itself is biologically inac-
tive and must be converted to the active form 1,25-dihydroxy-
Vitamin D3 (1,25 Vitamin D3) in the kidneys (13–15). Vitamin 
D3 is important for calcium metabolism, bone health, cardiac 
function, and blood pressure maintenance, among other health 
benefits (14, 16, 17). Vitamin D3 deficiency is a marker of poor 
health and overall mortality (16). However, 40–50% of Americans 
have insufficient Vitamin D3 levels, and insufficiency is even 
more prevalent in underserved populations, including Hispanics 
(69%) and African Americans (82%) (18).
viTAMiN D3 iN THe BRAiN AND  
NeRvOUS SYSTeM
Among its variety of health benefits, Vitamin D3 plays an 
important role in the human brain and nervous system, as 
indicated by increasing evidence gathered over the past several 
decades. Researchers have explored the role of Vitamin D3 in 
Alzheimer’s disease and dementias (19, 20), Parkinson’s disease 
(19, 21), multiple sclerosis (22–24), schizophrenia (25), affective 
disorders (13, 26), cognitive decline (13, 27), and epilepsy (6, 12). 
Vitamin D3 is also involved in neuroprotection (15, 28, 29), brain 
cell proliferation and differentiation (30, 31), and brain develop-
ment (30, 32, 33). A neurological role of Vitamin D3 is further 
supported by the presence of Vitamin D3-specific receptors and 
enzymes in neurons and glial cells throughout the brain, in the 
spinal cord, and in the peripheral nervous system (34–37). The 
broad role of Vitamin D3 in the nervous system has engendered 
research into Vitamin D3’s anticonvulsant action in the brain, and 
the proposed mechanisms of action can generally be categorized 
as either genomic or non-genomic.
Genomic Mechanisms of Action
Genomic mechanisms behind Vitamin D3’s anticonvulsant effect 
are based on Vitamin D3’s ability to regulate the expression of 
genes, a process that is mediated by a nuclear Vitamin D3 recep-
tor (VDR) (38). VDR is a ligand-specific transcription factor, 
which is activated by Vitamin D3 and subsequently alters gene 
expression (28, 29). Through this mechanism, Vitamin D3 lowers 
the expression of certain proconvulsant cytokines, such as IL-1β 
and TNF-α. These cytokines can increase seizure susceptibility 
in several ways. IL-1β is involved in a pathway that results in 
phosphorylation of the NR2B subunit of the NMDA receptor, 
which is a glutamate receptor that is important in the generation 
of seizures (39). The phosphorylation of this NMDA receptor 
subunit increases Ca2+ influx into neurons (40) and stabilizes the 
receptor in the membrane (41), leading to the hyperexcitability 
of neurons that can cause seizures (39, 42). IL-1β can also cause 
neuronal hyperexcitability by increasing the release probability 
of glutamate (43), an excitatory neurotransmitter, and inhibiting 
its reuptake (39, 44). In addition, IL-1β can reduce inhibitory 
GABA-ergic Cl− flux (45), furthering the proconvulsant effect of 
this cytokine (39). The TNF-α cytokine acts as a proconvulsant 
because it initiates both the recruitment of AMPA receptors to 
the neuronal membrane and the endocytosis of GABAA recep-
tors away from the membrane (46, 47). The TNF-α-induced 
overexpression of AMPA receptors and under-expression of 
GABAA receptors on the neuronal membranes results in more 
excitatory synaptic transmission and less inhibitory signaling, 
which increases the likelihood of epileptic activity.
Through its nuclear VDR, Vitamin D3 can also increase 
the expression of anticonvulsant growth factors GDNF and 
NT3 (15,  29, 48–50). NT3 leads to an anticonvulsant effect by 
downregulating TrkA and TrkC receptors, which are receptors 
that regulate synaptic strength (50). The mechanism behind 
GDNF’s anticonvulsant action remains largely unknown, but 
it is speculated that, similar to that of NT3, it involves some 
modulation of synaptic transmission (51). Vitamin D3-activated 
VDR also promotes expression of the calcium-binding proteins 
parvalbumin and calbindins, which inhibit epileptic episodes 
(15, 29, 52). By binding to Ca2+ in the presynaptic terminal, these 
calcium-binding proteins prevent excessive Ca2+-induced neu-
rotransmitter release and thus protect against epileptic activity 
(52, 53).
Non-Genomic Mechanisms of Action
Faster, non-genomic mechanisms of Vitamin D3’s anticonvulsant 
effect have been proposed as well. Vitamin D3’s ability to increase 
calcium uptake from the intestine can alter plasma and brain 
Ca2+ concentrations, which may decrease neuronal excitability 
and prevent seizures. However, evidence suggests that Vitamin 
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D3’s anticonvulsant effect is not wholly attributable to its role 
in altering calcium levels (6, 8, 9). Rather, it is more likely that 
Vitamin D3’s rapid, anticonvulsant effect results from its ability 
to fine-tune Ca2+ and Cl− currents across neuronal membranes 
(54, 55). Vitamin D3 initiates non-genomic signal transduction 
pathways that ultimately alter the conductance of L-type calcium 
channels and chloride channels, therefore affecting neuronal 
excitability and seizure susceptibility at the threshold level 
(55–57). The details of these non-genomic signal transduction 
pathways are debated, and although it used to be thought that 
they were mediated by a distinct membrane Vitamin D3 receptor 
(VDRmem) (58), more recent evidence suggests that these rapid, 
non-genomic anticonvulsant pathways are actually mediated by 
the same protein – VDR – that mediates Vitamin D3’s genomic 
actions (54, 57, 59–61), with different domains of VDR being 
involved in the genomic and non-genomic pathways that lead to 
Vitamin D3’s anticonvulsant effects.
viTAMiN D3 iN ANiMAL MODeLS  
OF SeiZUReS
Rat Models
In 1984, Siegel et  al. published a seminal paper describing the 
effect of Vitamin D3 on seizure thresholds in rat hippocampi 
(7). Using artificial electrical stimulation to model seizures, they 
found that stereotactic injection of 50 or 100 μg of 1,25 Vitamin 
D3 into the hippocampus of rats significantly elevated the seizure 
threshold in all rats treated. This elevation in threshold was notice-
able 5–10  min after the injection of 1,25 Vitamin D3, and the 
effect lasted at least 120–180 min. Intravenous injection of 1,25 
Vitamin D3 also significantly elevated seizure threshold, but the 
effect was transient, lasting only 30 min, perhaps due to limited 
uptake of 1,25 Vitamin D3 in the brain. Most rats were Vitamin 
D3-sufficient, but they found that in one Vitamin D3-deficient 
rat, a lower dose of 1,25 Vitamin D3 was required to raise the 
seizure threshold to a similar extent.
Mouse Models
Over two decades after Siegel et  al.’s rat study, Kalueff et  al. 
explored the anticonvulsant effects of Vitamin D3 in a mouse 
model of seizures (8). Subcutaneous injection of 33 μg of 1,25 
Vitamin D3 incurred an anticonvulsant effect in a chemi-
cally induced model of seizures. Compared to controls, mice 
injected with 1,25 Vitamin D3 40 min prior to the injection of 
pentylenetetrazol (PTZ), a seizure-inducing chemical, exhibited 
longer mean latency to seizure onset (77 vs. 55 s), shorter mean 
duration of tonic–clonic seizures (10 vs. 32 s), and lower mor-
tality (18 vs. 55%). However, the anticonvulsant effects of 1,25 
Vitamin D3 were nearly gone if Vitamin D3 injection occurred 
3, 6, 12, or 24 h before PTZ injection. The acute efficacy of 1,25 
Vitamin D3 suggests that the anticonvulsant effect in this model 
was due to non-genomic actions of the steroid. In addition, dif-
ferences in Ca2+ levels between control and experimental mice 
were non-significant, suggesting that 1,25 Vitamin D3 exerted 
an anticonvulsant effect independent of its role in calcium 
metabolism (8).
In a separate study, Kalueff et al. found that the partial deletion 
of the VDR gene in mice led to increased seizure severity in the 
model of PTZ-induced seizures (9). Compared to wild-type mice, 
VDR-knockout mice demonstrated significantly shorter latencies 
to seizure onset (50.4 vs. 66.9 s), higher Racine scores of seizure 
severity (5.9 vs. 4.9), and increased mortality (90 vs. 40%). Of note, 
none of the mice in either the control or experimental condition 
showed spontaneous seizure activity, suggesting that the VDR 
gene acts at the threshold level of seizures. Both wild-type and 
VDR-knockout mice had normal calcium levels, suggesting that 
the partial deletion of the VDR gene increases seizure intensity 
via a non-calcium mechanism and providing further evidence of 
an anticonvulsant effect of Vitamin D3 that is independent from 
its role in calcium metabolism (9).
In two studies, Borowicz et al. have shown that certain doses of 
Vitamin D3 enhance the efficacy of several AEDs in a mouse elec-
troshock model of epilepsy without altering the concentrations of 
the drugs, suggesting a synergistic pharmacological interaction 
(10, 11). The authors also reported some anticonvulsant action 
of Vitamin D3 in its own right (10), and they found that treat-
ment with Vitamin D3 led to no deleterious changes in motor 
coordination, long-term memory, or anxiety (10, 11).
Overall, existing evidence from rat and mouse studies supports 
an acute anticonvulsant effect of Vitamin D3 in electric shock 
and chemically induced models of seizure. Further research is 
needed to explore the longer-term effects of Vitamin D3 therapy 
in diverse animal models of epilepsy.
viTAMiN D3 iN HUMAN ePiLePSY
People with epilepsy are often Vitamin D3-deficient, along with 
having decreased bone density and higher rates of osteoporosis 
(62). Furthermore, certain AEDs, such as carbamazepine and 
phenytoin, are known to decrease Vitamin D3 levels in people 
who are taking them due to increased metabolic clearance of 
Vitamin D3 and conversion to inactive forms (63, 64). People 
with epilepsy face a sixfold risk for bone fracture compared to 
the normal population, likely an interplay between frequent 
falls, reduced bone density, and low levels of Vitamin D3 (62). 
Maternal Vitamin D3 deficiency during pregnancy has also been 
associated with hypocalcemia-induced seizures in neonates, 
which have been successfully treated with calcium and Vitamin 
D3 supplementation in several case studies (65–68).
In humans, little clinical data exist about the effect of Vitamin 
D3 supplementation on seizures. In 1974, Christiansen et  al. 
conducted a pilot study in which they treated 23 epilepsy patients 
with Vitamin D3 (6). Subjects were divided into two groups 
(A  and B) for the duration of the 12-week study, which was 
divided into a 4-week observation phase (T1) followed by two 
4-week treatment periods (T2 and T3). Group A (n = 9) received 
4,000 IU/day of Vitamin D3 during T2, followed by 16,000 IU/
day during T3. Group B (n =  14) received placebo during T2, 
followed by 8,000 IU/day of Vitamin D3 during T3. During T2, 
Group A (treated with 4,000 IU/day of Vitamin D3) experienced 
a mean reduction in seizure frequency of 32% from baseline, 
while Group B (placebo) experienced an 8% reduction in mean 
seizure frequency from baseline. During T3, Group A (treated 
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with 16,000 IU/day of Vitamin D3) experienced a 29% reduction 
in mean seizure frequency from baseline, while Group B (being 
treated with 8,000 IU/day of Vitamin D3) experienced a similar. 
In both groups, high dose vitamin D3 (8000 to 16000 IU/day) was 
associated with reductions in seizure frequency 33% reduction 
in mean seizure frequency from baseline. The authors concluded 
that high dose Vitamin D3 significantly reduced the number of 
seizures in patients with poorly controlled epilepsy, and, contrary 
to the authors’ hypothesis, it did so independently of calcium or 
magnesium levels (6).
Nearly 40 years after Christiansen et al.’s findings, Holló et al. 
conducted the most recent clinical study of Vitamin D3 therapy 
in human epilepsy (12). Their subjects consisted of 13 patients 
with DRE. At baseline, low 25-OH-Vitamin D3 levels <30 ng/
ml were present in 12/13 patients and deficient levels (<12 ng/
ml) were present in 8/13 patients; 1/13 patients had a normal 
Vitamin D3 level at baseline. Treatment consisted of Vitamin D3 
supplementation aimed at normalizing the serum Vitamin D3 
levels of all the subjects. To the 12 patients with low or deficient 
Vitamin D3 levels at baseline, an oral dose of 40,000–200,000 IU 
bolus of Vitamin D3 was administered, and treatment was 
continued with a daily maintenance dose of 2,000–2,600 IU/day 
of Vitamin D3. The one subject with normal baseline Vitamin 
D3 level only received the daily maintenance doses. Vitamin D3 
levels were rechecked 3 months after treatment onset to deter-
mine successful normalization of Vitamin D3 levels and rule 
out potential Vitamin D3 toxicity. Vitamin D3 supplementation 
was determined to be safe, as no subjects showed toxic levels of 
Vitamin D3 at the 3-month follow-up (12). Median Vitamin D3 
level rose from 11.8  ng/ml at baseline (range: <4–34.2  ng/ml) 
to 38.0  ng/ml at 3-month follow-up (range: 23.3–45.0  ng/ml). 
This elevation in Vitamin D3 levels was significant (p = 0.001, 
sign test), and the posttreatment Vitamin D3 levels of all subjects 
were within or close to the normal range (12). The efficacy of 
the Vitamin D3 treatment in reducing seizures was determined 
by comparing the number of seizures experienced during the 
90 days prior to treatment onset to the number of seizures expe-
rienced in the 90 days after treatment onset. Among all subjects, 
10/13 experienced fewer seizures after initialization of Vitamin 
D3 treatment, 2/13 had more seizures, and 1/13 had the same 
number of seizures. The median reduction in seizure number fol-
lowing treatment onset was 40% and was significant (p = 0.04). In 
addition, 5/13 patients experienced a ≥50% reduction in number 
of seizures. The existing clinical evidence suggests a therapeutic 
effect of Vitamin D3 in human epilepsy, but there is a need for 
larger Phase I trials and Phase II randomized, placebo-controlled 
trials to investigate optimal dosing and short-term and long-term 
efficacy.
DOeS viTAMiN D3 HAve A POTeNTiAL 
ROLe iN ReDUCiNG SUDeP RiSK?
Vitamin D3 status is strongly associated with risk of sudden 
cardiac death in heart disease and patients with severe kidney 
disease on hemodialysis. In a large prospective study of 2,300 
patients in the Cardiovascular Health Study, the risk of sudden 
cardiac death was 2-times higher in those with Vitamin D3 levels 
<20 ng/ml (4 events/1,000) than in those with Vitamin D3 levels 
>20  ng/ml (2 events/1,000) (69). Similarly, in a study of 1,108 
patients with chronic kidney disease, very low levels of Vitamin 
D3 (25-hydroxy-Vitamin D3 levels <25  nmol/l) were 3-times 
more likely to sustain sudden cardiac death than those with high 
levels >75 nmol/l (hazard ratio = 2.99) (70).
Common to severe heart and kidney disease is impaired 
heart rate variability (HRV), particularly vagus-mediated high-
frequency HRV (69–72). Patients with DRE, who are at high 
risk for SUDEP, have impaired vagus-mediated HRV, similar in 
magnitude to patients with heart failure (69, 70, 73, 74). Recently, 
subjects with DRE, at high risk of SUDEP, as measured by the 
SUDEP-7 inventory, were found to have severe impairment in 
RMSSD, a measure of vagus-mediated HRV (73, 74). In a recent 
study linking SUDEP risk in patients with DRE, those with the 
highest SUDEP-7 inventory risk scores in the highest quartile had 
RMSSD values of 17.6 ms, vs. 32.0 ms for those with the lowest 
SUDEP-7 inventory scores (p = 0.03, trend test) (74). This finding 
is relevant since Vitamin D3 supplementation improves vagus-
mediated HRV (71, 72, 75). Recently, Vitamin D3 supplementa-
tion ranging from 5,000 to 10,000 IUs in normal controls resulted 
in significant improvements in high-frequency HRV, as measured 
by the low-frequency/high-frequency HRV ratio (75). A similar 
result was recently found in patients with IGA nephropathy, 
where high-frequency HRV, as measured by the LF/HF HRV 
ratio, also increased after Vitamin D3 supplementation (71).
CONCLUSiON AND FUTURe DiReCTiONS
The weight of evidence from basic research and animal models 
over the past several decades supports an anticonvulsant effect 
of Vitamin D3. Vitamin D3’s anticonvulsant action may be via 
genomic and non-genomic mechanisms. Epidemiological data as 
well as a variety of case studies also point to a connection between 
Vitamin D3 and epilepsy and support the use of Vitamin D3 as a 
potential therapy for human epilepsy, both in its own right and in 
conjunction with existing AEDs. However, the clinical data that 
exist are limited by small sample size and/or lack of randomiza-
tion and double-blind placebo control. Despite these limitations, 
existing clinical data have, in the opinion of this review, been 
positive enough to warrant larger Phase I and Phase II clinical 
trials in order to more rigorously determine the potential thera-
peutic value of Vitamin D3 as a treatment for human epilepsy. 
Recently, our group has received an IND for a Phase I study of 
Vitamin D3 in DRE to study the safety, preliminary efficacy, and 
potential cardiac benefits of Vitamin D3 5,000 IU/day in DRE.
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